Novo Nordisk announced its latest earnings to investors today. Ozempic & Wegovy sales now total $49.74 billion since Ozempic’s 2018 launch. Stock buybacks and dividends total $44.38 billion over the same period. Meanwhile, Novo Nordisk’s self-reported research & development investments for the perio...